{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.37","upperLimit":"23.04","value":"17.2"},{"groupId":"OG001","lowerLimit":"11.40","upperLimit":"21.96","value":"16.2"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.31","upperLimit":"66.97","value":"60.3"},{"groupId":"OG001","lowerLimit":"52.23","upperLimit":"66.12","value":"59.3"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.89","upperLimit":"17.15","value":"12.0"},{"groupId":"OG001","lowerLimit":"9.32","upperLimit":"19.22","value":"13.7"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.00","upperLimit":"9.81","value":"5.7"},{"groupId":"OG001","lowerLimit":"2.38","upperLimit":"8.83","value":"4.9"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.12","upperLimit":"3.41","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.12","upperLimit":"3.50","value":"1.0"}]}],"title":"Unable to evaluate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.67","upperLimit":"7.40","value":"3.8"},{"groupId":"OG001","lowerLimit":"2.38","upperLimit":"8.83","value":"4.9"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"BOR observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease \\& disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by baseline scan \\& no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic \\& hepatic nodules, involvement of other organs is usually assessable \\& no measurable disease should be present, SD: Failing to attain criteria needed for a CR/PR, but not fulfilling those for PD, PD: appearance of any new lesion \\>1.5 cm in any axis during or at end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in SPD of any previously involved nodes, or in single involved node, or size of other lesions (e.g., splenic or hepatic nodules). IRC review was performed up clinical cutoff date of to 1 May 2015.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had at least one post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline until PD or death, whichever occurred first (up to approximately 5 years)","title":"Percentage of Participants With Best Overall Response (BOR) as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}